Wed, Aug 27, 2014, 5:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan Dec 19, 2012 10:04 AM Flag

    NHS approves payment off Kalydec in the UK

    Earlier than expected, NHS is paying for Kalydeco=upward revision in earnings for 2013.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • read the press release. it says it doesn't work on the 508 mutation. I thought they were testing that now or next year. Guess i need to go back and read other posts on expanded CF trials.

      • 1 Reply to chevymalibu1966
      • Chevy, No snark intended, but you need to read up much more on the CF stuff. qdelfan correctly pointed out that Kalydeco was approved by England ahead of schedule and you told him to read the press release that it wouldn't work for 508. Kalydeco is labeled for 551 (not df508) and as recently as 2 weeks ago Vertex said that it wasn't rushing to negotiate a price on Kalydeco and that it expected reimbursements in England and EU and Canada to be coming throughout 2013. So this is much earlier than expected and likely at a good price for Vertex because it indicated it was holding out to protect the value of its drug. It also bodes well for further increased revenues when the Kalydeco label is expanded as Vertex already has a negotiated price for Kalydeco. Right now waiting on FDA to approve the study design for 809/770 which could be announced any day now.

 
VRTX
93.03-0.61(-0.65%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.